Mylan N.V. (NASDAQ:MYL) was the target of some unusual options trading on Wednesday. Stock investors acquired 16,282 call options on the stock. This represents an increase of 531% compared to the average volume of 2,581 call options.
Several brokerages have weighed in on MYL. Cowen and Company restated a “hold” rating and set a $30.00 price objective (down from $43.00) on shares of Mylan N.V. in a research note on Wednesday, August 9th. Royal Bank Of Canada restated a “sector perform” rating and set a $32.00 price objective (down from $33.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. Citigroup Inc. upgraded Mylan N.V. from a “neutral” rating to a “buy” rating and raised their price objective for the company from $36.00 to $42.00 in a research note on Wednesday, August 16th. Wells Fargo & Company set a $32.00 price objective on Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $48.00 price objective (up from $44.00) on shares of Mylan N.V. in a research note on Friday. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $41.99.
Shares of Mylan N.V. (NASDAQ:MYL) opened at 38.29 on Friday. The company has a 50-day moving average price of $32.08 and a 200 day moving average price of $36.45. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87. The stock has a market cap of $20.53 billion, a price-to-earnings ratio of 30.95 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.16 earnings per share. Equities research analysts expect that Mylan N.V. will post $4.57 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock valued at $1,808,088,000 after acquiring an additional 1,165,852 shares during the period. BlackRock Inc. lifted its holdings in Mylan N.V. by 4.5% in the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock valued at $1,575,089,000 after acquiring an additional 1,751,515 shares during the period. Vanguard Group Inc. lifted its holdings in Mylan N.V. by 12.0% in the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after acquiring an additional 3,531,974 shares during the period. State Street Corp lifted its holdings in Mylan N.V. by 1.6% in the second quarter. State Street Corp now owns 20,498,541 shares of the company’s stock valued at $795,751,000 after acquiring an additional 321,977 shares during the period. Finally, Pzena Investment Management LLC lifted its holdings in Mylan N.V. by 69.9% in the second quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock valued at $479,027,000 after acquiring an additional 5,077,371 shares during the period. 71.97% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/10/07/traders-purchase-high-volume-of-mylan-n-v-call-options-myl.html.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.